Peer-reviewed veterinary case report
How cannabidiol (CBD) is absorbed in dogs after oral and mouth dosing
By Della Rocca, Giorgia et al.·Published in Frontiers in veterinary science·2022·Department of Veterinary Medicine, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs.
- Species:
- dog
Plain-English summary
A group of twelve dogs with mild chronic pain were given cannabidiol (CBD) either by mouth or through the cheek (oral transmucosal administration) to see which method worked better. The study found that both methods resulted in similar levels of CBD in the dogs' blood, meaning that using CBD in oil form didn't absorb better through the mouth than when swallowed. This suggests that CBD is mainly absorbed in the stomach rather than through the mouth. Pet owners should know that both methods are effective, but there isn't a significant advantage to one over the other.
People also search for: dog chronic pain treatment · CBD oil for dogs · oral vs transmucosal CBD for dogs
Abstract
INTRODUCTION: In the last few years, different formulations containing cannabidiol (CBD) were tested with regard to its efficacy on chronic pain, refractory epilepsy, anxiety, aggressive behavior and atopic dermatitis in dogs. CBD is generally administered orally, but its low bioavailability, probably due to a first-pass metabolism, represents a great limitation. The aim of this study was to evaluate if CBD bioavailability increases after oral transmucosal administration (OTM) compared to oral treatment. METHODS: Twelve dogs diagnosed with mild chronic pain were enrolled in the study and treated once orally or OTM (6 dogs/group) with a pure CBD in oil formulation at a dosing rate of 1 mg/kg b.w. At prefixed time points, blood samples were collected to define CBD plasma concentrations vs. time profiles, and the main pharmacokinetics parameters were obtained by non-compartmental model. RESULTS: CBD Cmax, Tmax, terminal half-life and AUCwere 206.77 ± 167 and 200.33 ± 158.33 ng/mL, 2.17 ± 0.98 and 1.92 ± 1.11 h, 2.67 ± 0.53 and 2.62 ± 0.64 h, 647.51 ± 453.17, and 536.05 ± 370.21 hng/mL, following oral and OTM administration, respectively. No significant difference in pharmacokinetic parameters were observed between treatments. DISCUSSION: The OTM administration did not increase cannabidiol bioavailability compared to oral treatment. The almost perfectly superimposable mean plasma concentrations of cannabidiol following the two treatments suggests that CBD is not able to be adsorbed by the oral mucosa or that its absorption is very scarce, and that CBD is swallowed and absorbed in the gastrointestinal tract.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/36686155/